SCHEMBL17035934

SCHEMBL17035934

CC(C)(C)OC(=O)NCc1ncccn1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.47
NAMPT P43490 2/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
KDM4E B2RXH2 3/20 0.44
CYP1A2 P05177 1/20 0.44
LMNA P02545 1/20 0.44
BCHE P06276 1/20 0.43
CYP3A4 P08684 1/20 0.42
BRD4 O60885 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
ATR Q13535 1/20 0.40
AKT1 P31749 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13865274 0.83 L3MBTL1 (0.44) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL21106557 0.82 L3MBTL1 (0.43) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL18591337 0.82 L3MBTL1 (0.43) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL25097603 0.82 L3MBTL1 (0.43) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL15240003 0.82 STK17B (0.46) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL24756661 0.82 MAPKAPK2 (0.44) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL13977598 0.82 KDM4E (0.49) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL17038772 0.82 TSHR (0.43) KDM4EMEN1KMT2A
SCHEMBL16410303 0.82 ATR (0.47) KDM4ANAMPTL3MBTL1KDM4ECYP1A2
SCHEMBL4678395 0.81 SMN1; SMN2 (0.61) L3MBTL1KDM4EMEN1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298085-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-20170298085-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-9732103-B2 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-9732103-B2 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-20150239919-A1 Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298085-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS CFD, C9, CFH KDM4A 1516/4885NAMPT 3684/4885L3MBTL1 1693/4885
US-20150239919-A1 Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders CFD, C9, CFH KDM4A 1516/4885NAMPT 3684/4885L3MBTL1 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.